Literature DB >> 8833909

Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.

E A Elliott1, H I McFarland, S H Nye, R Cofiell, T M Wilson, J A Wilkins, S P Squinto, L A Matis, J P Mueller.   

Abstract

It has been shown that peripheral T cell tolerance can be induced by systemic antigen administration. We have been interested in using this phenomenon to develop antigen-specific immunotherapies for T cell-mediated autoimmune diseases. In patients with the demyelinating disease multiple sclerosis (MS), multiple potentially autoantigenic epitopes have been identified on the two major proteins of the myelin sheath, myelin basic protein (MBP) and proteolipid protein (PLP). To generate a tolerogenic protein for the therapy of patients with MS, we have produced a protein fusion between the 21.5-kD isoform of MBP (MBP21.5) and a genetically engineered form of PLP (deltaPLP4). In this report, we describe the effects of treatment with this agent (MP4) on clinical disease in a murine model of demyelinating disease, experimental autoimmune encephalomyelitis (EAE). Treatment of SJL/J mice with MP4 after induction of EAE either by active immunization or by adoptive transfer of activated T cells completely prevented subsequent clinical paralysis. Importantly, the administration of MP4 completely suppressed the development of EAE initiated by the cotransfer of both MBP- and PLP-activated T cells. Prevention of clinical disease after the intravenous injection of MP4 was paralleled by the formation of long-lived functional peptide-MHC complexes in vivo, as well as by a significant reduction in both MBP- and PLP-specific T cell proliferative responses. Mice treated with MP4 were resistant to disease when rechallenged with an encephalitogenic PLP peptide emulsified in CFA, indicating that MP4 administration had a prolonged effect in vivo. Administration of MP4 was also found to markedly ameliorate the course of established clinical disease. Finally, MP4 therapy was equally efficacious in mice defective in Fas expression. These results support the conclusion that MP4 protein is highly effective in suppressing disease caused by multiple neuroantigen epitopes in experimentally induced demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8833909      PMCID: PMC507593          DOI: 10.1172/JCI118954

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  67 in total

1.  T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis.

Authors:  J M Critchfield; M K Racke; J C Zúñiga-Pflücker; B Cannella; C S Raine; J Goverman; M J Lenardo
Journal:  Science       Date:  1994-02-25       Impact factor: 47.728

2.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.

Authors:  S Brocke; K Gijbels; M Allegretta; I Ferber; C Piercy; T Blankenstein; R Martin; U Utz; N Karin; D Mitchell; T Veromaa; A Waisman; A Gaur; P Conlon; N Ling; P J Fairchild; D C Wraith; A O'Garra; C G Fathman; L Steinman
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

3.  Human myelin basic protein (MBP) epitopes recognized by mouse MBP-selected T cell lines from multiple sclerosis patients.

Authors:  Y K Chou; R E Jones; D Bourdette; R Whitham; G Hashim; J Atherton; H Offner; A A Vandenbark
Journal:  J Neuroimmunol       Date:  1994-01       Impact factor: 3.478

4.  Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.

Authors:  E Meinl; F Weber; K Drexler; C Morelle; M Ott; G Saruhan-Direskeneli; N Goebels; B Ertl; G Jechart; G Giegerich
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

5.  Purification of immunologically active recombinant 21.5 kDa isoform of human myelin basic protein.

Authors:  S H Nye; C M Pelfrey; J J Burkwit; R R Voskuhl; M J Lenardo; J P Mueller
Journal:  Mol Immunol       Date:  1995-10       Impact factor: 4.407

6.  Intravenous antigen administration as a therapy for autoimmune demyelinating disease.

Authors:  M K Racke; J M Critchfield; L Quigley; B Cannella; C S Raine; H F McFarland; M J Lenardo
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

7.  Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination.

Authors:  A H Cross; V K Tuohy; C S Raine
Journal:  Cell Immunol       Date:  1993-02       Impact factor: 4.868

8.  Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  J Zhang; S Markovic-Plese; B Lacet; J Raus; H L Weiner; D A Hafler
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

9.  Encephalitogenicity of myelin basic protein exon-2 peptide in mice.

Authors:  R B Fritz; M L Zhao
Journal:  J Neuroimmunol       Date:  1994-04       Impact factor: 3.478

10.  Experimental allergic encephalomyelitis induced by the peptide encoded by exon 2 of the MBP gene, a peptide implicated in remyelination.

Authors:  B M Segal; C S Raine; D E McFarlin; R R Voskuhl; H F McFarland
Journal:  J Neuroimmunol       Date:  1994-04       Impact factor: 3.478

View more
  17 in total

Review 1.  Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice.

Authors:  David Luckey; Dikshya Bastakoty; Ashutosh K Mangalam
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

2.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

Authors:  Cassandra E Smith; Stephen D Miller
Journal:  J Autoimmun       Date:  2006-12       Impact factor: 7.094

3.  Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis.

Authors:  G C Suvannavejh; M C Dal Canto; L A Matis; S D Miller
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

4.  IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.

Authors:  Duncheng Wang; Debjani Ghosh; S M Touhidul Islam; Cody D Moorman; Ashton E Thomason; Daniel S Wilkinson; Mark D Mannie
Journal:  J Immunol       Date:  2016-09-12       Impact factor: 5.422

5.  Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice.

Authors:  Y Katz-Levy; K L Neville; A M Girvin; C L Vanderlugt; J G Pope; L J Tan; S D Miller
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

6.  Viral infection triggers central nervous system autoimmunity via activation of CD8+ T cells expressing dual TCRs.

Authors:  Qingyong Ji; Antoine Perchellet; Joan M Goverman
Journal:  Nat Immunol       Date:  2010-06-06       Impact factor: 25.606

Review 7.  Dendritic cells as therapeutic targets in neuroinflammation.

Authors:  Felix Luessi; Frauke Zipp; Esther Witsch
Journal:  Cell Mol Life Sci       Date:  2016-03-12       Impact factor: 9.261

8.  Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene.

Authors:  Ming-Chao Zhong; Nicole Kerlero de Rosbo; Avraham Ben-Nun
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

9.  Bolus injection of aqueous antigen leads to a high density of T-cell-receptor ligand in the spleen, transient T-cell activation and anergy induction.

Authors:  S K Switzer; B P Wallner; T J Briner; G H Sunshine; C R Bourque; M Luqman
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

10.  Fundamental differences in the dynamics of CNS lesion development and composition in MP4- and MOG peptide 35-55-induced experimental autoimmune encephalomyelitis.

Authors:  Stefanie Kuerten; Sita Javeri; Magdalena Tary-Lehmann; Paul V Lehmann; Doychin N Angelov
Journal:  Clin Immunol       Date:  2008-08-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.